EVO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 39 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVO as a result. In 87 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for EVO entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +7.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 186 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (43.873). P/E Ratio (476.190) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PRGO advanced for three days, in 180 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on PRGO as a result. In 50 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for PRGO just turned positive on October 12, 2026. Looking at past instances where PRGO's MACD turned positive, the stock continued to rise in 26 of 41 cases over the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 88 of 186 cases where PRGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 47%.
The 10-day RSI Indicator for PRGO moved out of overbought territory on September 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 24 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
PRGO broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PRGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.833) is normal, around the industry mean (43.873). PRGO's P/E Ratio (2818.000) is considerably higher than the industry average of (141.710). Projected Growth (PEG Ratio) (1.142) is also within normal values, averaging (2.152). PRGO's Dividend Yield (0.077) is considerably higher than the industry average of (0.005). P/S Ratio (0.454) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
EVO | PRGO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 51 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 90 | 37 | |
P/E GROWTH RATING 1..100 | 2 | 2 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRGO's Valuation (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (89) in the null industry. This means that PRGO’s stock grew somewhat faster than EVO’s over the last 12 months.
PRGO's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that PRGO’s stock grew similarly to EVO’s over the last 12 months.
EVO's SMR Rating (96) in the null industry is in the same range as PRGO (98) in the Pharmaceuticals Other industry. This means that EVO’s stock grew similarly to PRGO’s over the last 12 months.
PRGO's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (90) in the null industry. This means that PRGO’s stock grew somewhat faster than EVO’s over the last 12 months.
PRGO's P/E Growth Rating (2) in the Pharmaceuticals Other industry is in the same range as EVO (2) in the null industry. This means that PRGO’s stock grew similarly to EVO’s over the last 12 months.
| EVO | PRGO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 64% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 62% |
| Advances ODDS (%) | 15 days ago 67% | 3 days ago 64% |
| Declines ODDS (%) | 2 days ago 80% | 14 days ago 69% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 47% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EVO’s FA Score shows that 1 FA rating(s) are green while PRGO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EVO’s TA Score shows that 4 TA indicator(s) are bullish while PRGO’s TA Score has 4 bullish TA indicator(s).
EVO (@Pharmaceuticals: Generic) experienced а -17.48% price change this week, while PRGO (@Pharmaceuticals: Generic) price change was +9.79% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -6.14%. For the same industry, the average monthly price growth was -6.23%, and the average quarterly price growth was +10.91%.
EVO is expected to report earnings on Nov 05, 2026.
PRGO is expected to report earnings on Nov 11, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BSCX | 20.16 | N/A | +0.01% |
| Invesco BulletShares 2033 Corporate Bond ETF (BSCX) | |||
| FMQQ | 12.55 | -0.01 | -0.04% |
| FMQQ The Next Frontier Internet ETF (FMQQ) | |||
| IBII | 24.52 | -0.01 | -0.04% |
| iShares iBonds Oct 2032 Term TIPS ETF (IBII) | |||
| BEDY | 28.94 | -0.02 | -0.07% |
| BNY Mellon Enhanced Dividend and Income ETF (BEDY) | |||
| TVC | 23.74 | -0.06 | -0.25% |
| Tennessee Valley Authority Power Bonds 1998 Series D due June 1 2028 | |||
A.I.dvisor indicates that over the last year, PRGO has been loosely correlated with SUPN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PRGO jumps, then SUPN could also see price increases.
| Ticker / NAME | Correlation To PRGO | 1D Price Change % | ||
|---|---|---|---|---|
| PRGO | 100% | -0.52% | ||
| SUPN - PRGO | 49% Loosely correlated | -1.87% | ||
| ELAN - PRGO | 37% Loosely correlated | -0.66% | ||
| EVO - PRGO | 35% Loosely correlated | -1.82% | ||
| ALVO - PRGO | 34% Loosely correlated | -2.18% | ||
| PBH - PRGO | 34% Loosely correlated | -1.02% | ||
More | ||||